GlassScriptPhysician profile
Stuart Ian Anderson
NPI 1750342564
$4,424.61
in general payments reported to CMS, 2019-2025
21 companies · $907 in 2025
The $907 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $208 · 2021: $302 · 2022: $606 · 2023: $933 · 2024: $889 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,729.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $887.19 | 2022-2025 | Infuse, Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $757.46 | 2022-2025 | Acuvue |
| Coopervision INC. | $636.84 | 2020-2025 | Misight Contact Lens, Paragon Crt, Myday Contact Lens |
| Alcon Vision LLC | $383.60 | 2021-2025 | Precision 1, Dailies Total1, Tryptyr |
| Lumenis Be INC | $381.78 | 2023 | Optilight |
| Tarsus Pharmaceuticals, INC. | $199.60 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $152.01 | 2020-2024 | Lipiflow System Activator (Disposable) |
| Kala Pharmaceuticals, INC. | $138.53 | 2021 | |
| Glaukos Corporation | $133.95 | 2025 | Photrexa Viscous and Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.00 | 2019 | |
| Shire North American Group INC | $125.00 | 2019 | |
| Ivantis, INC | $125.00 | 2019 | |
| Aerie Pharmaceuticals, INC. | $123.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $80.91 | 2021-2023 | |
| Hoffmann-La Roche Limited | $46.20 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Synergeyes, INC. | $34.90 | 2019 | |
| Sun Pharmaceutical Industries INC. | $25.65 | 2025 | |
| Lkc Technologies, INC. | $22.94 | 2025 | |
| Abbvie INC. | $20.45 | 2022 | |
| Biotissue Holdings INC. | $13.34 | 2024 | |
| Allergan, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.